C54 TREATMENT OF PULMONARY HYPERTENSION: Ambrisentan In Patients With Portopulmonary Hypertension A Multicenter Open Label Trial von Preston, I R, Burger, C D, Krowka, M, Safdar, Z, Love, H, Visnaw, K, Sood, N, Bartolome, S, d, H J, Kim, N H, Poch, D, Hill, N S

Volltext

Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2) von Al‐Naamani, Nadine, Krowka, Michael J., Forde, Kimberly A., Krok, Karen L., Feng, Rui, Heresi, Gustavo A., Dweik, Raed A., Bartolome, Sonja, Bull, Todd M., Roberts, Kari E., Austin, Eric D., Hemnes, Anna R., Patel, Mamta J., Oh, Jae K., Lin, Grace, Doyle, Margaret F., Denver, Nina, Andrew, Ruth, MacLean, Margaret R., Fallon, Michael B., Kawut, Steven M., Timmerman, Kasi, Mottram, C.D., Scanlon, Paul D., Miller, Adam, Visnaw, Karen, Homer, Natalie, Andrew, Ruth, Abbott, Cheryl, Palevsky, Harold I., Rajender Reddy, K., Goldberg, David S., Khungar, Vandana, Akaya Smith, K., Fritz, Jason S., Lynch, Marita, Sharkoski, Tiffany, Pinder, Diane, Machicao, Victor, Rubin, Moises Nevah, Walker, Kim, Cranford, Stacy, Varing, Jordan, Banga, Namrata, Igenoza, Oluwatosin, LaRochelle, Celeste

Volltext